NCT05470504View on ClinicalTrials.gov

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Insulin Receptor MutationPartial Lipodystrophy
Interventions
DRUG

Pegvisomant

30 mg subcutaneously every day for 4 weeks.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH